Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jintiange (Jin Tian Ge) is a traditional Chinese medicine product developed as a substitute for tiger bone (tiger bone powder), which was historically used in China for its purported benefits on bone health. Due to conservation concerns and legal bans on the use of tiger products, Jintiange was formulated using bionic tiger bone powder derived from the bones of farmed edible animals such as pigs, goats, and deer. The capsule contains bioactive peptides, proteins, amino acids, and minerals similar to those found in natural tiger bone. It is approved by the Chinese Food and Drug Administration for clinical use primarily in osteoporosis therapy but has also been studied for other metabolic bone diseases such as osteoarthritis and rheumatoid arthritis. Mechanistically, it appears to modulate osteoblastogenesis (bone formation) and osteoclastogenesis (bone resorption), thereby improving bone microstructure and biomechanical properties. Clinical studies have shown efficacy in reducing pain scores (VAS), improving functional outcomes (ODI), alleviating musculoskeletal symptoms associated with aromatase inhibitors, and treating osteoporosis[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jintiange.